Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Etude expérimentale d'un nouveau sulfamide hypoglycémiant particulièrement actif, le HB 419 ou glibenclamide

Etude expérimentale d'un nouveau sulfamide hypoglycémiant particulièrement actif, le HB 419 ou... 125 5 5 1 1 Prof. Dr. A. Loubatières M. M. Mariani G. Ribes H. de Malbosc J. Chapal Institut de Biologie Faculté de Médecine Boulevard Henri IV Montpellier France Summary Glibenclamide or HB 419 is a new, particularly active hypoglycaemic sulphonylurea. In the normal, conscious dog, HB 419 administered intravenously was 240 or 440 times more active than tolbutamide, depending on whether the dosage is expressed in grams or in moles. The hypoglycaemic effect did not occur in the totally pancreatectomized dog. HB 419 stimulated insulin secretion. HB 419 administered intravenously in the anaesthetized dog increased insulinaemia in the pancreatico-duodenal vein for 7 h, which represents the duration of the experiment. After oral administration of 2 mg/kg, the increase of peripheral insulinaemia persisted for 24 h. Hyperinsulinaemia was also found in the pancreaticoduodenal vein in the conscious dog, when a catheter was permanently inserted into the said vein. The direct insulinsecreting effect has been shown on the isolated, perfused rat pancreas in vitro . This drug also counteracted the inhibitory effect of diazoxide on insulin-secretion both in vivo and in vitro . — Furthermore, this drug potentiated the effects of insulin in the pancreatectomized dog. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetologia Springer Journals

Etude expérimentale d'un nouveau sulfamide hypoglycémiant particulièrement actif, le HB 419 ou glibenclamide

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/etude-exp-rimentale-d-un-nouveau-sulfamide-hypoglyc-miant-particuli-0e0ZmQddxF

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 1969 by Springer-Verlag
Subject
Medicine & Public Health; Human Physiology; Internal Medicine; Metabolic Diseases
ISSN
0012-186X
eISSN
1432-0428
DOI
10.1007/BF01212212
Publisher site
See Article on Publisher Site

Abstract

125 5 5 1 1 Prof. Dr. A. Loubatières M. M. Mariani G. Ribes H. de Malbosc J. Chapal Institut de Biologie Faculté de Médecine Boulevard Henri IV Montpellier France Summary Glibenclamide or HB 419 is a new, particularly active hypoglycaemic sulphonylurea. In the normal, conscious dog, HB 419 administered intravenously was 240 or 440 times more active than tolbutamide, depending on whether the dosage is expressed in grams or in moles. The hypoglycaemic effect did not occur in the totally pancreatectomized dog. HB 419 stimulated insulin secretion. HB 419 administered intravenously in the anaesthetized dog increased insulinaemia in the pancreatico-duodenal vein for 7 h, which represents the duration of the experiment. After oral administration of 2 mg/kg, the increase of peripheral insulinaemia persisted for 24 h. Hyperinsulinaemia was also found in the pancreaticoduodenal vein in the conscious dog, when a catheter was permanently inserted into the said vein. The direct insulinsecreting effect has been shown on the isolated, perfused rat pancreas in vitro . This drug also counteracted the inhibitory effect of diazoxide on insulin-secretion both in vivo and in vitro . — Furthermore, this drug potentiated the effects of insulin in the pancreatectomized dog.

Journal

Diabetologia – Springer Journals

Published: Feb 1, 1969

There are no references for this article.